These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 21434938)

  • 1. Development, clinical evaluation, and post-licensure impact of RotaTeq, a pentavalent rotavirus vaccine.
    Goveia MG; Ciarlet M; Owen KE; Ranucci CS
    Ann N Y Acad Sci; 2011 Mar; 1222():14-8. PubMed ID: 21434938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.
    Ciarlet M; Schödel F
    Vaccine; 2009 Dec; 27 Suppl 6():G72-81. PubMed ID: 20006144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.
    Vesikari T; Clark HF; Offit PA; Dallas MJ; DiStefano DJ; Goveia MG; Ward RL; Schödel F; Karvonen A; Drummond JE; DiNubile MJ; Heaton PM
    Vaccine; 2006 May; 24(22):4821-9. PubMed ID: 16621194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.
    Vesikari T; Itzler R; Karvonen A; Korhonen T; Van Damme P; Behre U; Bona G; Gothefors L; Heaton PM; Dallas M; Goveia MG
    Vaccine; 2009 Dec; 28(2):345-51. PubMed ID: 19879226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rotavirus live, oral, pentavalent vaccine.
    Tom-Revzon C
    Clin Ther; 2007 Dec; 29(12):2724-37. PubMed ID: 18201590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine.
    Chandran A; Santosham M
    Expert Rev Vaccines; 2008 Dec; 7(10):1475-80. PubMed ID: 19053204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A critical time for rotavirus vaccines: a review.
    Cunliffe NA; Nakagomi O
    Expert Rev Vaccines; 2005 Aug; 4(4):521-32. PubMed ID: 16117709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new pentavalent rotavirus vaccine composed of bovine (strain WC3) -human rotavirus reassortants.
    Clark HF; Offit PA; Plotkin SA; Heaton PM
    Pediatr Infect Dis J; 2006 Jul; 25(7):577-83. PubMed ID: 16804425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines: the pentavalent rotavirus vaccine: discovery to licensure and beyond.
    Heaton PM; Ciarlet M
    Clin Infect Dis; 2007 Dec; 45(12):1618-24. PubMed ID: 18198497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and biological characterization of the 5 human-bovine rotavirus (WC3)-based reassortant strains of the pentavalent rotavirus vaccine, RotaTeq.
    Matthijnssens J; Joelsson DB; Warakomski DJ; Zhou T; Mathis PK; van Maanen MH; Ranheim TS; Ciarlet M
    Virology; 2010 Aug; 403(2):111-27. PubMed ID: 20451234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life.
    Block SL; Vesikari T; Goveia MG; Rivers SB; Adeyi BA; Dallas MJ; Bauder J; Boslego JW; Heaton PM;
    Pediatrics; 2007 Jan; 119(1):11-8. PubMed ID: 17200266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis.
    Heaton PM; Goveia MG; Miller JM; Offit P; Clark HF
    J Infect Dis; 2005 Sep; 192 Suppl 1():S17-21. PubMed ID: 16088800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RotaTeq: Progress toward developing world access.
    Goveia MG; Nelson CB; Ciarlet M
    J Infect Dis; 2010 Sep; 202 Suppl():S87-92. PubMed ID: 20684723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of rotavirus: Implications for child health.
    Bishop R
    J Gastroenterol Hepatol; 2009 Oct; 24 Suppl 3():S81-5. PubMed ID: 19799704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rotavirus vaccines.
    Vesikari T
    Scand J Infect Dis; 2008; 40(9):691-5. PubMed ID: 19086243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children.
    Vesikari T; Karvonen AV; Majuri J; Zeng SQ; Pang XL; Kohberger R; Forrest BD; Hoshino Y; Chanock RM; Kapikian AZ
    J Infect Dis; 2006 Aug; 194(3):370-6. PubMed ID: 16826486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RotaTeq vaccine adverse events and policy considerations.
    Geier DA; King PG; Sykes LK; Geier MR
    Med Sci Monit; 2008 Mar; 14(3):PH9-16. PubMed ID: 18301365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on Rotarix: an oral human rotavirus vaccine.
    O'Ryan M; Linhares AC
    Expert Rev Vaccines; 2009 Dec; 8(12):1627-41. PubMed ID: 19943758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotavirus vaccines: new drug. Rotavirus infection: one case of severe diarrhoea prevented per 100 vaccinated infants.
    Prescrire Int; 2007 Feb; 16(87):3-6. PubMed ID: 17323513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency.
    Goveia MG; DiNubile MJ; Dallas MJ; Heaton PM; Kuter BJ;
    Pediatr Infect Dis J; 2008 Jul; 27(7):656-8. PubMed ID: 18520448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.